Wai Keen currently leads the Pilot Plant Network and External Manufacturing Team within Biologics Development at Bristol Myers Squibb (BMS). He manages a team of scientists and engineers responsible for operations (upstream & downstream) of an integrated pilot plant and provides strategic management of external drug substance manufacturing activities in the CDMO space. Prior to BMS, Wai Keen has worked at Ultragenyx, Biogen and AstraZeneca where he worked on early and late stage downstream processes for mAbs, Bispecific antibodies, Fusion proteins, Fabs, ADCs, protein conjugates and AAVs. Wai Keen holds a PhD in Chemical & Biological Engineering from Rensselaer Polytechnic Institute and BS/MS in Biochemical Engineering from University College London.